Home・Akciju saraksts・Pfizer

Pfizer

Slēgts

SektorsVeselības aprūpe

28.09 3.01

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

26.86

Max

27.37

Galvenie mērījumi
By Trading Economics
Ienākumi	-2.9B -238M
Pārdošana	583M 15B
P/E Sektora vidējais	35.355 57.371
EPS	0.77
Dividenžu ienesīgums	6.42
Peļņas marža	-1.583
Darbinieki	75,000
EBITDA	-3.8B 1.2B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+6.1% upside

Dividendes
By Acuity
Dividenžu ienesīgums Sektora vidējais	6.42% 2.23%
Nākamie ieņēmumi	2026. g. 3. nov.
Nākamais dividenžu datums	2026. g. 1. sept.
Nākamais Ex dividenžu datums	2026. g. 6. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	10B 153B
Iepriekšējā atvēršanas cena	25.08
Iepriekšējā slēgšanas cena	28.09

Ziņu noskaņojums

By Acuity

35%

65%

128 / 340 Rangs Healthcare

Pfizer Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. aug. 19:16 UTC

Social Media

Event

Pfizer reported second-quarter adjusted EPS of $0.77, exceeding estimates, and raised its sales outlook for fiscal year 2026, with shares trading higher.

2026. g. 17. aug. 23:36 UTC

Event

Pfizer Inc shares are lower in after-market hours following the announcement of Xtandi's new indication for prostate cancer treatment. The broader market also declined.

2026. g. 14. aug. 23:51 UTC

Pfizer Inc. shares are higher in after-market hours amid broader economic concerns following a reported decline in U.S. retail sales for July.

2026. g. 13. aug. 23:16 UTC

Pfizer Inc shares are lower in after-market hours following a decline from earlier gains. No specific news was identified to explain the movement.

2026. g. 12. aug. 23:02 UTC

Social Media

News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

2026. g. 11. aug. 19:26 UTC

News

Pfizer Inc. shares are lower amid a $44 million settlement over its Chantix drug, which allegedly contained a cancer-linked substance.

2026. g. 10. aug. 23:01 UTC

Pfizer Inc. shares are lower in after-market hours, continuing a decline since Monday's close amid rising Treasury yields and inflation concerns.

2026. g. 8. aug. 00:02 UTC

Pfizer Inc shares are lower in after-market hours with no specific news identified. Broader market concerns about interest rate hikes continue to influence sentiment.

2026. g. 7. aug. 23:01 UTC

Pfizer Inc shares are lower in after-market hours, reaching a session low earlier. No specific news was identified to explain the decline.

2026. g. 6. aug. 23:51 UTC

Pfizer Inc shares are lower in after-market hours. The decline follows increased crude oil prices and a strengthening U.S. dollar, contributing to market volatility.

2026. g. 5. aug. 23:02 UTC

Pfizer Inc shares are modestly higher in after-market hours, reaching a session high before pulling back slightly. No specific news was identified for the movement.

2026. g. 4. aug. 23:21 UTC

Pfizer Inc shares are lower in after-market hours, with no specific news identified for the decline. Broader market sentiment remains positive amid falling crude oil prices.

2026. g. 3. aug. 23:46 UTC

Social Media

Pfizer Inc shares are higher in after-market trading ahead of earnings. The stock remains above its 20-day moving average, reflecting positive market sentiment.

2026. g. 31. jūl. 23:06 UTC

Pfizer Inc shares are higher in after-market hours, reflecting slight gains since Friday's close. The stock remains near the upper end of its one-month range.

2026. g. 30. jūl. 23:26 UTC

Event

Pfizer shares are higher in after-market trading following Phase 3 trial results for LITFULO in nonsegmental vitiligo, despite three prior sessions of lower closes.

2026. g. 29. jūl. 23:16 UTC

News

Pfizer and BioNTech received European Commission approval for their XFG-adapted COVID-19 vaccine, valid across all EU member states. Shares are trading roughly flat after-market.

2026. g. 28. jūl. 23:26 UTC

Pfizer Inc shares are lower in after-market hours, reversing an earlier gain. The stock remains above its 20-day moving average.

2026. g. 27. jūl. 18:56 UTC

Pfizer Inc is trading higher, driven by gains in the Pharmaceuticals sub-sector. Shares pulled back earlier in the session from a session high.

2026. g. 24. jūl. 18:06 UTC

Pfizer Inc. shares are lower today, reflecting broader market trends. Earlier, shares fell significantly before partially recovering amid declining crude oil prices.

2026. g. 23. jūl. 09:41 UTC

News

Pfizer Inc. shares are higher in pre-market trading following FDA acceptance of a Priority Review for TALZENNA in combination with XTANDI for prostate cancer.

2026. g. 22. jūl. 23:02 UTC

News

Pfizer Inc. shares are higher in after-market hours following the FDA's acceptance of a Priority Review for TALZENNA and XTANDI in prostate cancer treatment.

2026. g. 21. jūl. 23:11 UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

2026. g. 20. jūl. 23:16 UTC

Pfizer Inc shares are higher in after-market trading, maintaining above their 20-day moving average despite broader market pressures from rising treasury yields.

Salīdzinājums

Cenas izmaiņa

Pfizer Prognoze

Cenas mērķis

By TipRanks

6.1% augšup

Prognoze 12 mēnešiem

Vidējais 28.51 USD 6.1%

Augstākais 35.75 USD

Zemākais 25 USD

Pamatojoties uz 21 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pfizer — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

21 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 21 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pfizer — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

128 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.